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Abstract	  
Objectives.	  A	  national	  audit	  was	  performed	  assessing	  the	  early	  management	  of	  suspected	  inflammatory	  
arthritis	  by	  English	  and	  Welsh	  rheumatology	  units.	  The	  aim	  of	  this	  audit	  was	  to	  measure	  the	  performance	  
of	  rheumatology	  services	  against	  National	  Institute	  for	  Health	  and	  Care	  Excellence	  (NICE)	  quality	  standards	  
(QSs)	  for	  the	  management	  of	  early	  inflammatory	  arthritis	  benchmarked	  to	  regional	  and	  national	  
comparators	  for	  the	  first	  time	  in	  the	  UK.	  
	  
Methods.	  All	  individuals	  >16	  years	  of	  age	  presenting	  to	  rheumatology	  services	  in	  England	  and	  Wales	  with	  
suspected	  new-­‐onset	  inflammatory	  arthritis	  were	  included	  in	  the	  audit.	  Information	  was	  collected	  against	  
six	  NICE	  QSs	  that	  pertain	  to	  early	  inflammatory	  arthritis	  management.	  
	  
Results.	  We	  present	  national	  data	  for	  the	  6354	  patients	  recruited	  from	  1	  February	  2014	  to	  31	  January	  2015;	  
97%	  of	  trusts	  and	  health	  boards	  in	  England	  and	  Wales	  participated	  in	  this	  audit.	  Only	  17%	  of	  patients	  were	  
referred	  by	  their	  general	  practitioner	  within	  3	  days	  of	  first	  presentation.	  Specialist	  rheumatology	  
assessment	  occurred	  within	  3	  weeks	  of	  referral	  in	  38%	  of	  patients.	  The	  target	  of	  DMARD	  initiation	  within	  6	  
weeks	  of	  referral	  was	  achieved	  in	  53%	  of	  RA	  patients;	  36%	  were	  treated	  with	  combination	  DMARDs	  and	  
82%	  with	  steroids	  within	  the	  first	  3	  months	  of	  specialist	  care.	  Fifty-­‐nine	  per	  cent	  of	  patients	  received	  
structured	  education	  on	  their	  arthritis	  within	  1	  month	  of	  diagnosis.	  In	  total,	  91%	  of	  patients	  had	  a	  
treatment	  target	  set;	  the	  agreed	  target	  was	  achieved	  within	  3	  months	  of	  specialist	  review	  in	  only	  27%	  of	  
patients.	  Access	  to	  urgent	  advice	  via	  a	  telephone	  helpline	  was	  reported	  to	  be	  available	  in	  96%	  of	  trusts.	  
	  
Conclusion.	  The	  audit	  has	  highlighted	  gaps	  between	  NICE	  standards	  and	  delivery	  of	  care,	  as	  well	  as	  




There	  is	  compelling	  evidence	  that	  the	  outcome	  of	  RA	  is	  dramatically	  improved	  by	  early	  diagnosis	  followed	  
by	  prompt	  and	  intensive	  treatment.	  However,	  there	  is	  also	  evidence	  that	  most	  health	  systems	  in	  
wealthy/developed	  nations	  struggle	  to	  provide	  early	  assessment	  and	  rapid	  access	  to	  treatment	  for	  people	  
with	  RA.	  In	  2009,	  the	  UK	  National	  Audit	  Office	  reported	  the	  cost-­‐effectiveness	  of	  early	  aggressive	  treatment	  
of	  RA	  as	  well	  as	  acknowledging	  significant	  geographical	  variation	  in	  RA	  care	  across	  the	  UK	  [1].	  In	  the	  same	  
year,	  the	  UK	  National	  Institute	  for	  Health	  and	  Care	  Excellence	  (NICE)	  published	  clinical	  guidance	  (CG79)	  for	  
the	  treatment	  of	  RA	  [2]	  emphasizing	  the	  importance	  of	  early	  diagnosis	  and	  treatment.	  In	  2013,	  NICE	  
published	  quality	  standards	  (QSs)	  for	  the	  diagnosis	  and	  treatment	  of	  RA	  (QS33)	  that	  summarize	  the	  
principles	  of	  rapid	  and	  intensive	  patient-­‐centred	  treatment	  [3].	  
	  
QS1,	  general	  practitioner	  (GP)	  referral	  time,	  states	  that	  people	  with	  suspected	  persistent	  synovitis	  
(swelling)	  affecting	  the	  small	  joints	  of	  the	  hands	  or	  feet,	  or	  more	  than	  one	  joint,	  should	  be	  referred	  to	  a	  
rheumatology	  service	  within	  3	  working	  days	  of	  presentation	  to	  their	  GP.	  
	  
QS2,	  waiting	  time,	  states	  that	  people	  with	  suspected	  persistent	  synovitis	  (swelling)	  should	  be	  assessed	  in	  a	  
rheumatology	  service	  within	  3	  weeks	  of	  referral.	  
	  
QS3,	  time	  to	  DMARD,	  states	  that	  people	  with	  newly	  diagnosed	  RA	  should	  be	  offered	  short-­‐term	  
glucocorticoids	  (steroids)	  and	  a	  combination	  of	  DMARDs	  by	  a	  rheumatology	  service	  within	  6	  weeks	  of	  
referral.	  
	  
QS4,	  education	  and	  self-­‐management,	  states	  that	  people	  with	  RA	  should	  be	  offered	  educational	  and	  self-­‐
management	  activities	  within	  1	  month	  of	  diagnosis.	  
	  
QS5,	  treat	  to	  target,	  states	  that	  people	  who	  have	  active	  RA	  should	  be	  offered	  monthly	  treatment	  escalation	  
until	  the	  disease	  is	  controlled	  to	  an	  agreed	  low	  disease	  activity	  target.	  
	  
QS6,	  urgent	  access,	  states	  that	  people	  with	  RA	  and	  disease	  flares	  or	  possible	  drug-­‐related	  side	  effects	  
should	  receive	  advice	  within	  1	  working	  day	  of	  contacting	  the	  rheumatology	  service.	  
	  
QS7,	  annual	  review,	  states	  that	  people	  with	  RA	  should	  have	  a	  comprehensive	  annual	  review	  that	  is	  co-­‐
ordinated	  by	  the	  rheumatology	  service.	  
	  
However,	  NICE	  clinical	  guidelines	  and	  QSs	  do	  not	  place	  any	  statutory	  obligations	  on	  National	  Health	  Service	  
(NHS)	  organizations	  in	  the	  UK.	  The	  provision	  of	  services	  is	  determined	  at	  local	  level,	  and	  anecdotal	  and	  local	  
audit	  data	  suggest	  that	  there	  is	  widespread	  variation	  in	  rheumatologic	  practice	  across	  the	  NHS.	  Hitherto	  
there	  have	  been	  no	  robust	  measures	  of	  this	  variation	  at	  national	  and	  local	  levels.	  
	  
For	  this	  reason,	  a	  national	  audit	  of	  the	  management	  of	  RA	  and	  early	  inflammatory	  arthritis	  (EIA)	  was	  
commissioned	  by	  the	  Healthcare	  Quality	  Improvement	  Partnership	  (HQIP)	  as	  part	  of	  the	  NHS	  National	  
Clinical	  Audit	  and	  Patient	  Outcome	  Programme.	  These	  audits	  generally	  assess	  quality	  of	  care	  against	  
nationally	  approved	  guidelines	  and	  provide	  detailed	  information	  on	  clinical	  and	  patient-­‐reported	  outcomes	  
to	  inform	  the	  wider	  NHS.	  For	  information	  about	  the	  background	  of	  the	  audit,	  please	  see	  the	  supplementary	  
data	  section	  on	  ‘Background	  and	  methodology	  for	  the	  UK	  national	  clinical	  audit	  for	  rheumatoid	  and	  EIA’,	  
available	  at	  Rheumatology	  Online.	  
	  
This	  audit	  aims	  to	  assess	  the	  early	  management	  of	  patients	  referred	  to	  English	  and	  Welsh	  rheumatology	  
trusts	  with	  suspected	  inflammatory	  arthritis	  and	  to	  enable	  patients	  to	  provide	  feedback	  on	  the	  services	  
provided	  to	  them	  and	  on	  the	  impact	  of	  their	  arthritis	  on	  their	  lives.	  The	  audit	  enables	  rheumatology	  
services	  to	  measure	  their	  performance	  against	  NICE	  QSs,	  benchmarked	  to	  regional	  and	  national	  
comparators	  for	  the	  first	  time.	  All	  NHS	  provider	  organizations	  have	  a	  contractual	  obligation	  to	  participate	  in	  
the	  National	  Clinical	  Audit	  and	  Patient	  Outcome	  Programme	  and	  hence	  the	  audit	  provides	  the	  first	  effective	  




The	  data	  collection	  tools	  were	  developed	  by	  the	  audit	  project	  working	  group,	  following	  extensive	  
consultation,	  and	  were	  approved	  for	  use	  by	  HQIP	  and	  the	  NHS	  Review	  of	  Central	  Returns	  (now	  the	  Burden	  
Advice	  and	  Assessment	  Service),	  who	  provide	  recommendations	  to	  minimize	  the	  burden	  of	  data	  collection.	  
Ethical	  approval	  was	  not	  required	  and	  further	  information	  on	  governance	  structures,	  the	  information	  
technology	  (IT)	  tool	  and	  on	  data	  security	  can	  be	  found	  in	  the	  supplementary	  data,	  available	  at	  
Rheumatology	  Online.	  
	  
The	  questionnaires	  and	  web-­‐based	  IT	  tool	  were	  piloted	  prior	  to	  the	  national	  audit	  launch	  in	  February	  2014.	  
Patient	  consent,	  using	  HQIP-­‐	  and	  Review	  of	  Central	  Returns–approved	  processes,	  was	  obtained	  for	  all	  
analysed	  data.	  This	  was	  sought	  from	  patients	  at	  the	  first	  appointment	  and	  recorded	  on	  the	  baseline	  audit	  
form.	  Consent	  guidance	  was	  provided	  to	  patients	  explaining	  the	  implications	  of	  agreeing	  to	  participate	  in	  
the	  audit,	  how	  any	  personal	  details	  would	  be	  used	  and	  that	  data	  would	  be	  anonymized	  for	  analysis	  and	  
publication.	  
	  
All	  individuals	  >16	  years	  of	  age	  presenting	  to	  specialist	  rheumatology	  services	  in	  England	  and	  Wales	  with	  
new-­‐onset	  peripheral	  joint	  polyarthritis	  were	  eligible	  for	  inclusion	  in	  the	  audit.	  Patients	  were	  recruited	  if	  
they	  had	  RA,	  PsA,	  peripheral	  arthritis	  linked	  with	  SpA	  (not	  pure	  axial	  SpA)	  and	  undifferentiated	  arthritis,	  but	  
were	  excluded	  if	  they	  had	  crystal	  arthritis	  or	  arthritis	  caused	  by	  infection	  (viral	  or	  septic	  arthritis)	  or	  linked	  
with	  CTDs/vasculitis.	  Clinician-­‐derived	  data	  were	  collected	  for	  3	  months	  from	  recruitment	  of	  each	  patient	  
with	  an	  RA	  pattern	  of	  disease	  in	  relation	  to	  the	  NICE	  QSs.	  Patient-­‐reported	  outcome	  and	  experience	  
measures	  and	  information	  on	  each	  patient’s	  ability	  to	  work	  were	  also	  collected.	  In	  addition,	  organizational	  
data	  were	  collected,	  including	  catchment	  population,	  staff	  numbers	  and	  availability	  of	  EIA	  clinics.	  Further	  




Data	  are	  presented	  for	  patients	  recruited	  from	  1	  February	  2014	  to	  31	  January	  2015.	  One	  hundred	  and	  
forty-­‐three	  of	  148	  eligible	  NHS	  rheumatology	  providers	  in	  England	  and	  Wales	  registered	  to	  participate	  in	  
the	  audit	  and	  94%	  of	  these	  supplied	  data.	  Data	  from	  6354	  patients	  were	  analysed,	  representing	  >40%	  of	  
expected	  incident	  RA	  cases	  based	  on	  an	  expected	  incidence	  from	  previous	  studies	  of	  15/100	  000	  [4,	  5].	  
	  
Tables	  1	  and	  2	  show	  the	  age,	  gender	  and	  ethnicity	  of	  patients.	  Patients	  were	  predominantly	  women	  (66%)	  
and	  70%	  were	  of	  working	  age	  (16–65	  years).	  A	  higher	  proportion	  of	  men	  were	  found	  in	  the	  >65	  year	  age	  
group	  (39%).	  By	  far	  the	  majority	  of	  patients	  recruited	  were	  of	  white	  British	  origin	  (79%),	  but	  there	  was	  
significant	  geographical	  variation	  in	  ethnicity,	  as	  shown	  in	  Table	  2.	  
	  
TABLE	  1	  Age	  and	  gender	  of	  participants	  
	  
Age	  group	   Total	  recruited	  during	  time	  window	  (12	  months)	  
	  
Male,	  n	  (%)	   Female,	  n	  (%)	   Total,	  n	  (%)	  
All	   2078	  (33.6)	   4108	  (66.4)	   6186	  (100.0)	  
Working	  age	  (16–65	  years)	   1353	  (31.1)	   2993	  (68.9)	   4346	  (70.3)	  
Non-­‐working	  age	  (>65	  years)	   725	  (39.4)	   1115	  (60.6)	   1840	  (29.7)	  
	  
	  
TABLE	  2	  Ethnicity	  of	  participants	  across	  NHS	  regions	  and	  Wales	  
	  
Ethnicity	   National,	  n	  (%)	   London,	  n	  (%)	   Midlands,	  n	  (%)	   North,	  n	  (%)	   South,	  n	  (%)	   Wales,	  n	  (%)	  
All	   6354	  (100)	   809	  (12.7)	   1374	  (21.6)	   2129	  (33.5)	   1676	  (26.4)	   366	  (5.8)	  
White	   4987	  (78.5)	   376	  (46.5)	   1149	  (83.6)	   1705	  (80.1)	   1435	  (85.6)	   322	  (88)	  
Black	   175	  (2.8)	   130	  (16.1)	   27	  (2.0)	   11	  (0.5)	   7	  (0.4)	   0	  (0.0)	  
Asian	   336	  (5.3)	   131	  (16.2)	   74	  (5.4)	   85	  (4.0)	   43	  (2.6)	   3	  (0.8)	  
Mixed	   106	  (1.7)	   41	  (5.1)	   27	  (2.0)	   17	  (0.8)	   19	  (1.1)	   2	  (0.6)	  
Not	  provided	   750	  (11.8)	   131	  (16.2)	   97	  (7.1)	   311	  (14.6)	   172	  (10.3)	   39	  (10.7)	  
	  
	  
At	  the	  first	  point	  of	  data	  collection,	  46%	  of	  patients	  had	  an	  established	  diagnosis	  of	  RA,	  16%	  had	  
undifferentiated	  EIA,	  10%	  had	  PsA,	  3%	  had	  peripheral	  joint	  disease	  linked	  with	  AS,	  9%	  had	  other	  forms	  of	  
EIA	  and	  16%	  had	  no	  data	  provided.	  
	  
There	  was	  wide	  variation	  in	  the	  number	  of	  consultants	  per	  100	  000	  population,	  with	  a	  mean	  nationally	  
(England	  and	  Wales)	  of	  1.1,	  which	  is	  below	  the	  Royal	  College	  of	  Physicians	  recommended	  levels	  of	  1.16	  [6];	  
the	  range	  was	  0.8	  (South	  of	  England)–1.2	  (Wales	  and	  the	  North	  of	  England).	  Higher	  numbers	  of	  specialist	  
nurses	  per	  100	  000	  population	  (national	  average	  1.1)	  were	  employed	  in	  regions	  with	  lower	  numbers	  of	  
consultants.	  
	  
Nationally	  only	  75%	  of	  trusts	  reported	  access	  to	  specialist	  physiotherapy	  (range	  44–86%),	  77%	  to	  specialist	  
occupational	  therapy	  (range	  44–89%)	  and	  55%	  to	  specialist	  podiatry	  services	  (range	  42–83%).	  
	  
QS	  1:	  GP	  referral	  time	  
Nationally	  only	  17%	  of	  patients	  were	  referred	  by	  their	  GP	  to	  rheumatology	  within	  3	  days	  of	  first	  
presentation.	  A	  quarter	  of	  patients	  waited	  >3	  months	  to	  be	  referred	  and	  the	  median	  time	  from	  first	  GP	  
contact	  to	  referral	  was	  34	  days.	  
	  
There	  was	  wide	  variation	  in	  the	  time	  intervals	  reported	  for	  this	  QS,	  with	  40%	  of	  patients	  in	  Wales	  but	  only	  
11%	  in	  the	  Midlands	  and	  East	  of	  England	  meeting	  this	  QS.	  The	  median	  and	  interquartile	  range	  (IQR)	  for	  the	  
time	  from	  GP	  presentation	  to	  rheumatology	  referral	  for	  each	  region	  and	  nationally	  are	  shown	  in	  Fig.	  1,	  and	  
was	  lowest	  in	  Wales	  [11	  days	  (IQR	  1–64)]	  and	  highest	  in	  the	  Midlands	  and	  East	  of	  England	  [47	  days	  (IQR	  18–
124)].	  Several	  trusts	  could	  not	  meet	  this	  QS	  for	  any	  patient.	  There	  were	  patients	  in	  all	  NHS	  regions	  that	  
waited	  >1	  year	  to	  be	  referred	  to	  rheumatology	  after	  presenting	  to	  their	  GP.	  Equally	  there	  were	  patients	  




FIG.	  1:	  Variability	  for	  NICE	  quality	  standard	  1	  across	  NHS	  regions	  and	  Wales	  
Red	  line	  shows	  national	  median	  waiting	  time.	  Boxes	  show	  median	  (blue	  line)	  and	  interquartile	  range	  (IQR).	  Whiskers	  
show	  1.5	  ×	  IQR	  and	  blue	  dots	  show	  outlying	  values.	  
	  
QS	  2:	  waiting	  time	  
Nationally	  only	  38%	  of	  patients	  met	  this	  QS.	  The	  median	  waiting	  time	  nationally	  was	  4	  weeks	  and	  25%	  of	  
patients	  waited	  >7	  weeks	  to	  be	  seen.	  Again	  there	  was	  wide	  variation	  in	  results	  across	  individual	  trusts	  and	  
across	  NHS	  regions;	  55%	  of	  patients	  seen	  in	  London	  and	  28%	  seen	  in	  Wales	  achieved	  this	  QS.	  The	  median	  
and	  IQR	  for	  each	  NHS	  region	  are	  shown	  in	  Fig.	  2.	  All	  NHS	  regions	  had	  patients	  seen	  on	  the	  same	  day	  as	  
receipt	  of	  GP	  referral	  and	  all	  with	  the	  exception	  of	  Wales	  had	  patients	  waiting	  times	  of	  >60	  days.	  Twelve	  




FIG.	  2:	  Variability	  in	  NICE	  quality	  standard	  2	  by	  NHS	  region	  and	  Wales	  
The	  red	  line	  represents	  the	  overall	  national	  median	  (4	  weeks).	  Boxes	  show	  median	  (blue	  line)	  and	  interquartile	  range	  
(IQR).	  Whiskers	  show	  1.5	  ×	  IQR	  and	  blue	  dots	  show	  outlying	  values.	  
For	  the	  subsequent	  QSs	  (3–5)	  data	  were	  analysed	  only	  for	  RA	  patients	  (defined	  by	  the	  presence	  of	  polyarticular	  
disease	  (more	  than	  five	  joints	  involved)	  or	  pauci-­‐articular	  disease	  with	  positive	  CCP	  antibodies.	  
	  
	  
QS3:	  time	  to	  DMARD	  
Table	  3	  summarizes	  the	  data	  for	  this	  QS.	  Fifty-­‐three	  per	  cent	  of	  RA	  patients	  were	  treated	  with	  DMARDs	  
within	  6	  weeks	  of	  referral.	  This	  QS	  was	  achieved	  for	  the	  lowest	  proportion	  of	  patients	  in	  Wales	  (48%)	  and	  
for	  the	  highest	  proportion	  of	  patients	  in	  the	  North	  of	  England	  (56%);	  one	  trust	  was	  unable	  to	  meet	  this	  QS	  
for	  any	  patient.	  
	  
TABLE	  3:	  Number	  and	  proportion	  of	  RA	  patients	  started	  on	  DMARD/steroids	  nationally	  and	  within	  NHS	  
regions	  and	  Wales	  
	  
Number	  of	  RA	  patients	  
diagnosed	  at	  baseline	  
or	  follow-­‐up	  
Number	  of	  RA	  patients	  
commenced	  on	  DMARDs	  
within	  6	  weeks,	  n	  (%)	  
Number	  of	  RA	  patients	  
commenced	  on	  steroids	  at	  
any	  time,	  n	  (%)	  
Number	  of	  RA	  patients	  
commenced	  on	  combination	  
DMARDs	  at	  any	  time,	  n	  (%)	  
National	   3268	   1727	  (53)	   2689	  (82)	   1183	  (36)	  
London	   318	   166	  (52)	   231	  (73)	   133	  (42)	  
Midland	  and	  
East	  of	  
England	   798	   388	  (49)	   646	  (82)	   308	  (39)	  
North	  of	  
England	   1067	   601	  (56)	   893	  (84)	   408	  (38)	  
South	  of	  
England	   867	   464	  (54)	   722	  (83)	   294	  (34)	  
Wales	   223	   108	  (48)	   197	  (88)	   40	  (18)	  
	  
Nationally	  the	  reported	  use	  of	  combination	  DMARDs	  within	  the	  first	  3	  months	  of	  specialist	  care	  was	  
relatively	  low,	  at	  36%;	  combination	  DMARD	  use	  was	  lowest	  in	  Wales	  (18%)	  and	  highest	  in	  London	  (42%).	  
Some	  trusts	  reported	  no	  use	  of	  combination	  DMARDs.	  
Eighty-­‐two	  per	  cent	  of	  RA	  patients	  were	  reported	  to	  have	  been	  treated	  with	  steroids	  at	  some	  point	  during	  
the	  audit.	  London	  and	  Wales	  used	  steroids	  for	  the	  lowest	  (73%)	  and	  highest	  (88%)	  proportion	  of	  patients,	  
respectively.	  
	  
QS4:	  education	  and	  self-­‐management	  
Nationally	  59%	  of	  patients	  were	  reported	  through	  clinician-­‐derived	  follow-­‐up	  data	  to	  have	  received	  
structured	  education	  on	  their	  arthritis	  within	  1	  month	  of	  diagnosis.	  Data	  from	  London	  indicated	  that	  this	  QS	  
was	  met	  for	  only	  38%	  of	  patients;	  the	  North	  of	  England	  was	  able	  to	  achieve	  this	  QS	  for	  the	  highest	  
proportion	  of	  patients	  (63%).	  Interestingly,	  London	  struggled	  to	  achieve	  this	  QS	  despite	  reporting	  the	  
highest	  number	  of	  specialist	  nurses	  per	  100	  000	  population	  (1.2)	  and	  the	  North	  of	  England	  achieved	  this	  QS	  
in	  the	  highest	  proportion	  of	  patients	  despite	  having	  the	  lowest	  number	  of	  nurses	  per	  100	  000	  population	  
(0.8).	  Again	  some	  trusts	  failed	  to	  meet	  this	  QS	  for	  any	  patient.	  
	  
QS5:	  treat	  to	  target	  
Data	  on	  setting	  and	  agreeing	  to	  treatment	  targets	  with	  patients	  were	  assessed	  for	  this	  QS.	  Potential	  targets	  
included	  remission,	  low	  disease	  activity	  or	  a	  functional	  target.	  Details	  on	  the	  actual	  target	  set	  have	  not	  
been	  analysed	  within	  the	  audit	  but	  are	  available	  to	  the	  individual	  trusts	  that	  provided	  data.	  Ninety-­‐one	  per	  
cent	  of	  patients	  nationally	  had	  a	  treatment	  target	  set.	  Wales	  set	  treatment	  targets	  in	  the	  lowest	  proportion	  
of	  patients	  (82%)	  and	  the	  South	  of	  England	  and	  the	  Midlands	  and	  East	  of	  England	  achieved	  this	  in	  the	  
highest	  proportion	  of	  patients	  (97%).	  
	  
Nationally	  90%	  of	  treatment	  targets	  set	  were	  reported	  to	  have	  been	  agreed	  with	  patients,	  with	  agreement	  
reported	  for	  the	  lowest	  proportion	  of	  patients	  in	  the	  Midlands	  and	  East	  of	  England	  (87%)	  and	  for	  the	  
highest	  proportion	  of	  patients	  in	  Wales	  (94%).	  
	  
When	  set	  from	  the	  first	  appointment	  for	  patients	  with	  a	  confirmed	  EIA	  diagnosis,	  this	  treatment	  target	  was	  
achieved	  by	  3	  months	  of	  specialist	  review	  in	  only	  27%	  of	  patients	  nationally,	  as	  shown	  in	  Fig.	  3.	  Treatment	  
targets	  were	  met	  for	  the	  lowest	  proportion	  of	  patients	  in	  London	  (23%)	  and	  for	  the	  highest	  proportion	  in	  
the	  South	  of	  England,	  North	  of	  England	  and	  in	  the	  Midlands	  and	  East	  of	  England	  (27%).	  Again	  there	  were	  




FIG.	  3:	  Proportion	  of	  RA	  patients	  who	  achieved	  a	  treatment	  target	  set	  at	  an	  earlier	  visit	  (whiskers	  show	  95%	  
CIs)	  
	  
QS6:	  urgent	  access	  
This	  standard	  was	  determined	  at	  the	  department	  level	  (rather	  than	  the	  individual	  patient	  level).	  Clinicians	  
reported	  access	  to	  urgent	  advice	  via	  a	  telephone	  helpline	  in	  96%	  of	  trusts,	  with	  very	  little	  national	  variation.	  
	  
QS7:	  annual	  review	  




This	  audit	  has	  allowed	  the	  first	  comprehensive	  national	  benchmarking	  of	  care	  given	  to	  people	  with	  newly	  
diagnosed	  inflammatory	  arthritis	  in	  England	  and	  Wales.	  Data	  quality	  was	  generally	  good,	  with	  data	  
collected	  from	  the	  vast	  majority	  of	  trusts.	  Missing	  data	  (detailed	  below)	  need	  to	  be	  borne	  in	  mind	  when	  
interpreting	  the	  results;	  very	  few	  baseline	  data	  were	  missing,	  but	  follow-­‐up	  data	  capture	  was	  more	  
challenging.	  
	  
Forty-­‐two	  trusts	  did	  not	  achieve	  the	  numbers	  of	  patients	  anticipated	  by	  their	  catchment	  population	  and	  
five	  trusts	  did	  not	  participate.	  Data	  collection	  for	  the	  audit	  was	  complex	  and	  time	  consuming	  and	  difficult	  to	  
accommodate	  in	  a	  busy	  clinical	  setting.	  Feedback	  suggests	  poor	  staffing	  levels	  and	  a	  lack	  of	  resources	  made	  
it	  difficult	  for	  some	  units	  to	  participate	  in	  the	  audit.	  
The	  population	  of	  patients	  recruited	  to	  this	  audit	  was	  largely	  as	  anticipated	  from	  epidemiological	  studies	  
[4,	  5].	  The	  data	  support	  recent	  evidence	  for	  an	  increasing	  age	  of	  onset	  of	  disease	  and	  possible	  increasing	  
incidence	  in	  men.	  
	  
The	  spread	  of	  confirmed	  diagnoses	  at	  the	  first	  appointment	  was	  also	  largely	  as	  anticipated.	  The	  vast	  
majority	  of	  patients	  had	  RA,	  with	  the	  next	  biggest	  group	  having	  undifferentiated	  arthritis,	  presumably	  
reflecting	  diagnostic	  uncertainty	  at	  the	  time	  of	  presentation.	  Very	  few	  patients	  had	  spondylitis	  when	  
presenting	  for	  the	  first	  time	  with	  a	  peripheral	  arthritis.	  
	  
Data	  for	  QS1	  (referral	  <3	  working	  days)	  were	  available	  for	  6220	  patients	  (98%);	  working	  days	  were	  not	  
distinguished	  from	  non-­‐working	  days.	  Data	  on	  the	  date	  of	  first	  GP	  presentation	  relied	  on	  a	  combination	  of	  
patient	  recall	  and	  the	  record	  in	  the	  GP	  referral	  letter.	  The	  record	  of	  the	  date	  of	  referral	  letter	  receipt	  was	  
complicated	  by	  the	  many	  and	  varied	  systems	  used	  by	  trusts	  for	  processing	  referrals/booking	  appointments.	  
Despite	  these	  considerations,	  there	  is	  clear	  evidence	  of	  significant	  delay	  between	  first	  presentation	  to	  a	  GP	  
and	  referral	  to	  rheumatology	  for	  most	  patients	  in	  England	  and	  Wales.	  These	  delays	  are	  consistent	  with	  data	  
from	  other	  more	  limited	  studies	  [7].	  The	  wide	  variation	  in	  results	  is	  likely	  to	  reflect	  considerable	  variations	  
in	  awareness	  of	  this	  QS	  among	  GPs,	  along	  with	  barriers	  within	  some	  localities	  to	  referral	  to	  rheumatology.	  
The	  fact	  that	  referral	  was	  made	  for	  some	  patients	  on	  the	  day	  of	  presentation	  to	  a	  GP	  in	  all	  NHS	  regions	  
suggests	  that	  for	  some	  patients	  and	  some	  GPs	  the	  decision	  to	  initiate	  referral	  is	  clearer	  than	  for	  others.	  This	  
highlights	  the	  need	  for	  rheumatology	  units	  to	  promote	  the	  importance	  of	  early	  referral	  for	  specialist	  
assessment	  and	  to	  help	  remove	  organizational	  barriers	  to	  timely	  referral.	  
	  
Data	  for	  QS2	  (assessment	  by	  rheumatology	  within	  3	  weeks)	  were	  available	  for	  6331	  patients	  (>99.5%).	  
Again	  there	  was	  noteworthy	  variation	  in	  the	  ability	  to	  meet	  this	  QS.	  The	  data	  highlight	  that	  even	  after	  
referral	  is	  initiated,	  there	  is	  significant	  delay	  in	  gaining	  a	  specialist	  assessment	  for	  a	  large	  proportion	  of	  
patients,	  and	  this	  impacts	  on	  the	  ability	  to	  meet	  other	  QSs	  and	  potentially	  on	  the	  ability	  to	  preserve	  joint	  
integrity	  and	  function.	  Higher	  levels	  of	  consultant	  staffing	  (>1	  consultant	  per	  100	  000	  population	  served)	  
and	  the	  presence	  of	  specific	  EIA	  clinics	  were	  found	  to	  significantly	  associate	  with	  shorter	  waiting	  times	  for	  a	  
specialist	  appointment	  [odds	  ratio	  1.3	  (95%	  CI	  1.1,	  1.4)	  and	  1.6	  (1.4,	  1.7),	  respectively].	  
	  
To	  assist	  in	  the	  processes	  for	  booking	  an	  urgent	  appointment,	  rheumatology	  units	  are	  encouraged	  to	  work	  
with	  primary	  care	  colleagues	  to	  establish	  systems	  promoting	  the	  provision	  of	  important	  information	  in	  
referral	  letters	  so	  that	  any	  potential	  for	  an	  inflammatory	  arthritis	  is	  clearly	  highlighted.	  Although	  not	  
directly	  assessed	  in	  this	  audit,	  processes	  in	  some	  trusts	  that	  do	  not	  allow	  clinicians	  to	  see	  referral	  letters,	  
and	  hence	  influence	  waiting	  times,	  are	  factors	  that	  are	  likely	  to	  impact	  on	  the	  ability	  to	  meet	  this	  QS	  that	  
may	  warrant	  review.	  This	  audit	  confirms	  that	  staffing	  levels	  can	  impact	  on	  the	  timeliness	  of	  appointments,	  
but	  how	  the	  configuration	  of	  staff	  and	  EIA	  clinics	  improve	  waiting	  times	  is	  yet	  to	  be	  elucidated	  and	  is	  a	  
recommended	  topic	  for	  future	  research.	  
	  
Data	  for	  QS3	  (treatment	  with	  glucocorticoids	  and	  combination	  DMARDs	  within	  6	  weeks)	  were	  missing	  for	  
1813	  clinician	  baseline	  forms	  (29%),	  so	  this	  needs	  to	  be	  borne	  in	  mind	  when	  interpreting	  the	  results.	  While	  
the	  overall	  statistic	  of	  slightly	  more	  than	  half	  of	  RA	  patients	  starting	  one	  or	  more	  DMARDS	  within	  6	  weeks	  
of	  referral	  might	  seem	  disappointing,	  the	  fact	  that	  only	  38%	  of	  patients	  are	  seen	  within	  3	  weeks	  of	  GP	  
referral	  suggests	  that	  most	  rheumatology	  services	  are	  swiftly	  starting	  DMARD	  treatment	  once	  a	  patient	  is	  
diagnosed.	  Steroids	  are	  much	  more	  widely	  used	  in	  the	  early	  stages	  of	  disease	  management	  than	  DMARDs	  
and	  clinicians	  use	  some	  form	  of	  disease-­‐modifying	  treatment	  (steroids	  and/or	  DMARDs)	  for	  the	  vast	  
majority	  of	  RA	  patients	  at	  the	  point	  of	  diagnosis	  and	  within	  the	  first	  3	  months	  of	  specialist	  care.	  There	  is	  
some	  suggestion	  that	  the	  approach	  to	  early	  management	  of	  RA	  differs	  across	  NHS	  regions;	  for	  example,	  
Wales	  had	  the	  highest	  use	  of	  steroids	  but	  the	  lowest	  use	  of	  DMARDs	  within	  6	  weeks	  and	  of	  combination	  
DMARDs.	  This	  would	  be	  a	  further	  potential	  topic	  for	  future	  research.	  There	  are	  a	  huge	  number	  of	  factors	  
that	  influence	  how	  rapidly	  RA	  treatment	  can	  be	  safely	  commenced	  and	  these	  need	  to	  be	  considered	  when	  
looking	  at	  the	  results	  for	  QS3.	  
	  
There	  may	  be	  inadequate	  time	  available	  at	  initial	  appointments	  to	  provide	  patients	  with	  sufficient	  
information	  to	  safely	  initiate	  treatment.	  The	  increasing	  requirement	  to	  establish	  a	  diagnosis,	  supply	  
adequate	  information	  to	  patients	  and	  gain	  consent	  to	  commence	  treatment	  at	  a	  single	  appointment	  has	  
not	  been	  accompanied	  by	  an	  increase	  in	  appointment	  duration	  in	  most	  units.	  The	  importance	  of	  giving	  
sufficient	  information	  about	  treatment	  risks	  and	  of	  gaining	  consent	  for	  treatment	  has	  been	  emphasized	  
with	  recent	  high-­‐profile	  UK	  court	  rulings	  such	  as	  the	  ‘Montgomery’	  case	  [8,	  9].	  Unless	  a	  one-­‐stop	  service	  is	  
available,	  a	  further	  appointment	  with	  a	  specialist	  nurse	  at	  a	  later	  date	  is	  usually	  required	  to	  implement	  
shared	  decision	  making	  prior	  to	  DMARD	  initiation.	  The	  lack	  of	  availability	  of	  baseline	  investigations,	  
particularly	  in	  patients	  with	  co-­‐morbidities,	  will	  also	  delay	  DMARD	  initiation	  for	  some	  patients.	  
	  
Staffing	  levels	  and	  the	  availability	  of	  timely	  follow-­‐up	  appointments	  become	  crucial	  if	  treatment	  is	  not	  
initiated	  at	  the	  first	  appointment;	  only	  6%	  of	  RA	  patients	  had	  timely	  (within	  6	  weeks	  of	  referral)	  initiation	  of	  
DMARD	  therapy	  from	  a	  follow-­‐up	  appointment.	  The	  reasons	  for	  this	  are	  clear:	  by	  the	  time	  most	  patients	  
had	  their	  first	  follow-­‐up	  appointment	  they	  had	  already	  passed	  the	  6	  week	  benchmark	  for	  QS3.	  
	  
Of	  interest,	  slightly	  more	  than	  one-­‐third	  of	  RA	  patients	  were	  started	  on	  combination	  DMARDs.	  The	  2013	  
European	  guidelines	  for	  the	  treatment	  of	  RA	  [10]	  allow	  the	  use	  of	  monotherapy.	  The	  reasons	  for	  this	  audit	  
finding	  warrant	  further	  research,	  but	  clinicians	  and	  patients	  may	  prefer	  the	  sequential	  introduction	  of	  
DMARD	  treatment	  to	  the	  immediate	  initiation	  of	  combination	  DMARDs.	  An	  inability	  to	  see	  patients	  
monthly	  for	  treatment	  escalation	  may	  have	  prevented	  initiation	  of	  combination	  DMARDs	  within	  the	  3	  
month	  time	  frame	  assessed	  with	  this	  audit.	  Clinicians	  and	  patients	  may	  have	  reservations	  about	  
combination	  therapy	  for	  patients	  with	  milder	  disease	  at	  presentation.	  
	  
Data	  for	  QS4	  (structured	  self-­‐management	  and	  education	  within	  1	  month)	  were	  available	  for	  2499	  patients	  
(80%)	  of	  those	  attending	  for	  follow-­‐up.	  Approximately	  one-­‐third	  of	  providers	  could	  not	  offer	  a	  structured	  
patient	  education	  and	  self-­‐management	  service	  within	  1	  month	  of	  diagnosis	  (QS4).	  It	  should	  be	  noted,	  
however,	  that	  wide	  CIs	  were	  observed	  for	  NHS	  regions	  and	  trusts	  with	  lower	  achievement	  rates	  for	  this	  QS.	  
No	  comment	  can	  be	  made	  on	  whether	  the	  problem	  when	  not	  achieving	  this	  QS	  was	  with	  availability	  of	  
education,	  its	  format	  or	  the	  ability	  to	  provide	  education	  within	  1	  month.	  As	  nursing	  staff	  are	  most	  likely	  to	  
provide	  this	  service,	  this	  relationship	  warrants	  further	  investigation.	  
	  
Data	  were	  available	  on	  initial	  treatment	  target	  setting	  (component	  of	  QS5)	  for	  6097	  patients	  (96%).	  
Reassuringly,	  the	  vast	  majority	  of	  clinicians	  report	  that	  they	  are	  setting	  treatment	  targets	  and	  agreeing	  to	  
these	  with	  their	  patients	  as	  a	  measure	  of	  compliance	  with	  QS5.	  No	  verification	  of	  these	  data	  has	  been	  
undertaken	  and	  no	  comment	  can	  be	  made	  on	  how	  reliably	  any	  such	  treatment	  target	  is	  set	  and	  
documented.	  The	  reasons	  for	  not	  agreeing	  to	  a	  treatment	  target	  with	  patients	  cannot	  be	  derived	  from	  the	  
data,	  but	  this	  may	  relate	  to	  time	  pressures	  within	  clinics.	  Patient	  verification	  of	  agreed	  upon	  targets	  was	  
not	  possible	  from	  the	  audit	  data.	  
	  
Since	  early	  control	  of	  inflammation	  is	  crucial	  in	  determining	  longer-­‐term	  outcomes,	  it	  is	  of	  concern	  that	  
only	  slightly	  more	  than	  one-­‐quarter	  of	  patients	  achieve	  the	  treatment	  target	  set	  from	  their	  first	  
appointment	  within	  3	  months	  of	  follow-­‐up.	  However,	  data	  were	  missing	  at	  follow-­‐up	  for	  1658	  patients	  
(47%).	  The	  reasons	  for	  the	  low	  achievement	  of	  treatment	  targets	  are	  not	  clear	  from	  the	  audit	  data.	  One	  
possible	  explanation	  is	  that	  the	  time	  frame	  for	  response	  was	  too	  short	  to	  truly	  assess	  response.	  Other	  
factors	  might	  include	  a	  limited	  capacity	  for	  intensive	  follow-­‐up;	  the	  use	  of	  suboptimal	  treatment	  regimes,	  
including	  the	  underuse	  of	  combination	  DMARDs	  and	  steroids;	  problems	  of	  compliance	  with	  treatment	  
and/or	  tolerance	  of	  treatment.	  
	  
Data	  were	  available	  for	  6338	  patients	  (>99.5%)	  for	  QS6.	  Virtually	  all	  patients	  were	  considered	  by	  their	  
clinicians	  to	  have	  rapid	  access	  to	  advice	  if	  needed,	  although	  it	  was	  not	  possible	  to	  determine	  the	  extent	  and	  
quality	  of	  the	  facilities	  offered	  by	  individual	  trusts	  from	  the	  data	  gathered.	  
	  
In	  summary,	  these	  data	  should	  prove	  invaluable	  to	  English	  and	  Welsh	  trusts	  when	  assessing	  any	  
requirement	  for	  service	  improvements	  and	  there	  are	  a	  number	  of	  examples	  where	  the	  data	  have	  already	  
been	  used	  to	  deliver	  improvements	  to	  patient	  care.	  
	  
The	  key	  recommendations	  arising	  from	  this	  first	  year’s	  data	  include	  that	  rheumatology	  health	  professionals	  
need	  to	  work	  closely	  with	  primary	  care	  colleagues	  to	  raise	  awareness	  of	  the	  symptoms	  and	  signs	  of	  EIA	  and	  
of	  the	  importance	  of	  early	  referral	  for	  diagnosis	  and	  treatment;	  that	  mechanisms	  for	  ensuring	  key	  
information	  are	  provided	  in	  referral	  letters	  from	  primary	  care	  should	  be	  explored,	  as	  this	  should	  help	  
rheumatology	  departments	  to	  prioritize	  appointments;	  that	  processes	  and	  capacity	  within	  rheumatology	  
services	  should	  be	  reviewed	  to	  ensure	  first	  appointments	  are	  available	  within	  3	  weeks;	  that	  intensive	  
treatment	  can	  be	  delivered	  in	  the	  crucial	  early	  stages	  of	  disease;	  that	  patients	  receive	  appropriate	  and	  
timely	  education	  packages	  and	  have	  access	  to	  rapid	  advice	  when	  needed	  and	  that	  further	  work	  is	  needed	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